Weiss Ratings Reaffirms Sell (D) Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)

Key Points

• Weiss Ratings has reaffirmed a "sell (d)" rating for Oramed Pharmaceuticals (NASDAQ:ORMP), indicating a negative outlook for the stock.
• Oramed Pharmaceuticals reported an EPS of ($0.05) for the latest quarter, missing analysts' estimates of ($0.04) by $0.01.
• Institutional investors have increased their stake in Oramed, with BML Capital Management raising its position by 14.3% in the first quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Oramed Pharmaceuticals Stock Performance

ORMP opened at $2.39 on Wednesday. The company's 50-day simple moving average is $2.27 and its two-hundred day simple moving average is $2.22. Oramed Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $3.09. The stock has a market capitalization of $97.99 million, a P/E ratio of -6.83 and a beta of 1.62.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). Research analysts forecast that Oramed Pharmaceuticals will post -0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock worth $6,464,000 after purchasing an additional 376,841 shares during the last quarter. N.E.W. Advisory Services LLC raised its position in Oramed Pharmaceuticals by 52.9% during the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 6,540 shares in the last quarter. Peapod Lane Capital LLC raised its position in Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after acquiring an additional 24,985 shares in the last quarter. Jane Street Group LLC raised its position in Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in Oramed Pharmaceuticals by 36.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 5,000 shares in the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.